Section of Endocrinology and Metabolism, Vakif Gureba Education and Research Hospital, Istanbul, Turkey.
Mol Cell Endocrinol. 2010 Jun 30;322(1-2):125-34. doi: 10.1016/j.mce.2010.02.001. Epub 2010 Feb 6.
TSH receptor (TSHR) germline mutations occur as activating mutations in familial non-autoimmune hyperthyroidism (FNAH) or sporadic non-autoimmune hyperthyroidism (SNAH). Up to date 17 constitutively activating TSHR mutations have been reported in 24 families with FNAH. The diagnosis of FNAH should be considered in cases with a positive family history, early onset of hyperthyroidism, goiter, absence of clinical stigmata of autoimmunity and recurrent hyperthyroidism. Moreover, 14 subjects with sporadic non-autoimmune hyperthyroidism and 10 different TSH receptor germline mutations have been reported. The main characteristic of SNAH is a negative family history. Additional consequences of prolonged neonatal hyperthyroidism (mental retardation, speech disturbances and craniosynostosis) have often been reported in SNAH. No genotype-phenotype relationship has been reported in patients with germline TSHR mutations. There is no association of in vitro activities determined by linear regression analysis (LRA) and several clinical indicators of hyperthyroidism activity for SNAH. However, the comparison of the LRA values of sporadic TSHR mutations with LRA values of familial TSHR mutations does show a significantly higher median LRA value for sporadic as compared to familial autosomal dominant hyperthyroidism. This finding is in line with the clinical impression of a more active clinical course in patients with SNAH. However, additional genetic, constitutional or environmental factors are most likely responsible for the phenotypic variations of the disease and the lack of correlation between in vitro activities of the TSHR mutations and the severity of hyperthyroidism.
促甲状腺激素受体 (TSHR) 种系突变作为激活突变发生在家族性非自身免疫性甲状腺功能亢进症 (FNAH) 或散发性非自身免疫性甲状腺功能亢进症 (SNAH) 中。迄今为止,已有 24 个 FNAH 家族报告了 17 种持续性激活的 TSHR 突变。如果存在阳性家族史、甲状腺功能亢进症早发、甲状腺肿、无自身免疫临床体征和复发性甲状腺功能亢进症,则应考虑 FNAH 的诊断。此外,还报告了 14 例散发性非自身免疫性甲状腺功能亢进症和 10 种不同的 TSH 受体种系突变。SNAH 的主要特征是阴性家族史。在 SNAH 中,经常报告新生儿期甲状腺功能亢进症持续时间较长的后果(智力低下、言语障碍和颅缝早闭)。在具有 TSHR 种系突变的患者中,尚未报告基因型-表型关系。在散发性 TSHR 突变中,线性回归分析 (LRA) 确定的体外活性与甲状腺功能亢进症活动的几个临床指标之间没有关联。然而,散发性 TSHR 突变的 LRA 值与家族性 TSHR 突变的 LRA 值的比较确实表明,散发性常染色体显性甲状腺功能亢进症的 LRA 值中位数明显高于家族性。这一发现与 SNAH 患者更活跃的临床病程的临床印象一致。然而,额外的遗传、体质或环境因素很可能是导致疾病表型变异的原因,并且 TSHR 突变的体外活性与甲状腺功能亢进症的严重程度之间缺乏相关性。